Hepatic Cirrhosis Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030

The global market value of hepatic cirrhosis was valued at USD 21.1 billion, and a CAGR of 5.8% is expected during the forecast period. Lifestyle disorders and the increasing prevalence of lever diseases are driving the growth of the market. Hepatitis C is among the most threatening chronic diseases. The increasing use of antiviral drugs to treat hepatitis, which causes liver inflammation, is driving the growth of the market significantly.

Increasing cases of bloodborne disease, the use of dirty water, and obesity lead to fatty liver disease. Excessive use of alcohol is also driving the growth of this market. Poor eating habits and unhealthy lifestyles are driving the growth of the market. The geriatric population is more susceptible to liver diseases in comparison to adults. Key players in the world are playing a pivotal role in spreading awareness among people regarding these diseases.

Impact of Covid-19

Due to a decline in demand for various drugs used in the treatment of lethal diseases and a shift in the priorities of people, the market is growing significantly. Stringent lockdown conditions and disruptions in the supply chain also caused a slowdown in the market. A remote health consultation was started after some time, which provided a solution for the liver patients.

Growth Drivers

Advancements in medical technology and increased awareness about liver diseases are driving the growth of the hepatic cirrhosis market. Expanding healthcare infrastructure and ongoing research for better treatment options are driving the market towards success. Ongoing research activities for better treatment options are also driving the growth of the market significantly. Advancement in treatment options, increased prevalence of liver disease, technological innovations in diagnostics, and a growing focus on early detection and prevention are driving the growth of this market significantly. According to the WHO, in certain regions of India, the number of patients is exponentially increasing. The rising incidence of non-alcoholic fatty liver diseases is driving the growth of the market. Pharmaceutical companies investing in research and development for novel therapies and effective drugs also play a significant role in shaping the market landscape.

Segmentation

Cause of Cirrhosis

·         Alcohol-Related

·         Viral Hepatitis

·         Non-Alcoholic Fatty Lever Diseases

Disease Severity Complication

·         Less Severe

·         Moderate Severe

·         Most Severe

By Treatment Type

·         Antiviral Drug

·         Vaccines

·         Targeted Therapy

·         Chemotherapy

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Europe

·         Middle East and Africa

Hepatic Cirrhosis Cause of Disease Type Segmentation

On the basis of cause of disease, the hepatic cirrhosis market is segmented into alcohol-related, viral hepatitis, and non-alcoholic fatty liver diseases. Alcohol-related hepatitis is the leading segment and is expected to dominate the market during the forecast period. Non-alcohol fatty liver disease covers a range of conditions where there is an accumulation of fat in the liver, often linked to lifestyle factors like obesity or insulin resistance. Alcohol-related hepatitis is liver inflammation caused by excessive alcohol consumption over time. It ranges from mild to severe and often occurs with alcohol-related liver diseases. Symptoms include jaundice, stomach pain, and liver enlargement.

Hepatic Cirrhosis Treatment Type Segmentation

On the basis of treatment type, the hepatic cirrhosis market is segmented into antiviral drugs, chemotherapy, radiotherapy, and targeted therapies. Antiviral drugs are the leading segment and are expected to dominate the market during the forecast period. Common treatments involve medications to manage symptoms like ascites and hepatic encephalopathy, along with therapies targeting the root cause, such as antiviral infections to target the root cause like hepatic infections, or lifestyle changes to manage underlying factors like alcohol abuse. Liver transplantation stands as a crucial treatment option. for end-stage liver diseases in cirrhosis patterns. Targeted therapies especially involve medications that specifically target certain molecules or pathways involved in the progression of liver diseases. These therapies aim to slow down disease progression. reduce complications or improve liver function by targeting specific cellular mechanisms. Chemotherapy is not the primary treatment for liver cirrhosis, but it is specifically used in cases of hepatocellular carcinoma. It develops due to the complications of cirrhosis. Chemotherapy drugs are used to reduce the size of tumors or control their growth.

Regional Outlook

On the basis of regional outlook, the hepatic cirrhosis market is segmented into 5 types: Asia Pacific, North America, Latin America, Europe, and Middle East and Africa. North America is the leading segment due to rising expenditure in healthcare infrastructure, increasing research and development activities, and rising disposable income. Innovation in technologies had driven the growth in the hepatic cirrhosis market. Unites States is the leading market worldwide due to modern advanced treatment methodology. Early diagnosis of the disease in the region is another reason behind the growth in the market.

High prevalence of liver diseases in the North American region, a robust healthcare infrastructure, advanced medical research, and increased investments in innovative treatments, is driving the growth in the market. Pharmaceutical companies have been actively involved in developing new therapies, and medications to address hepatic cirrhosis catering to specific needs of patients in this region. The market for hepatic cirrhosis treatment in the Asia pacific region has seen growth due to rising cases of liver diseases. Factors like improving healthcare infrastructure and increased awareness about liver health contributed to this market expansion. Multiple pharmaceutical companies have been developing and introducing medications targeting hepatic cirrhosis, aiming to cater to this specific region’s need.

India and China are the biggest markets in the region. The European market for hepatic cirrhosis treatment has been experiencing steady growth, driven by advancements in medical technology, increased research efforts, and a growing understanding of liver diseases. Pharmaceutical companies have been developing innovative therapies and medications to address the specific needs of patients in this region. Healthcare policies and initiatives aimed at improving liver health have contributed to the expansion of this market in Europe. Awareness campaigns and screening programs contribute to the market’s growth by promoting early detection and intervention.

Key Players

·         Bristol Myers Squibb

·         Emergent Bio Solutions INC

·         Gilead Sciences

·         Viatris INC

·         Astellas Pharma INC

·         Eli Lilly and Company

·         F. Hoffman La Roche AG

·         Merck. And Company

·         Abbott Laboratories

·         Other Players